The DOI matches its Crossref record; 271 of the 271 references it cites were found in a registry or an index.
Antifungal Resistance and New Strategies to Control Fungal Infections
Open accessAbstract
Despite improvement of antifungal therapies over the last 30 years, the phenomenon of antifungal resistance is still of major concern in clinical practice. In the last 10 years the molecular mechanisms underlying this phenomenon were extensively unraveled. In this paper, after a brief overview of currently available antifungals, molecular mechanisms of antifungal resistance will be detailed. It appears that major mechanisms of resistance are essential due to the deregulation of antifungal resistance effector genes. This deregulation is a consequence of point mutations occurring in transcriptional regulators of these effector genes. Resistance can also follow the emergence of point mutations directly in the genes coding antifungal targets. In addition we further describe new strategies currently undertaken to discover alternative therapy targets and antifungals. Identification of new antifungals is essentially achieved by the screening of natural or synthetic chemical compound collections. Discovery of new putative antifungal targets is performed through genome-wide approaches for a better understanding of the human pathogenic fungi biology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ghannoum, M. A., & Rice, L. B. (1999) · Clinical Microbiology Reviews · doi:10.1128/cmr.12.4.501 · Cited by 1,785
Clinical, Cellular, and Molecular Factors That Contribute to Antifungal Drug Resistance
White, T. C., Marr, K. A., & Bowden, R. A. (1998) · Clinical Microbiology Reviews · doi:10.1128/cmr.11.2.382 · Cited by 1,353
Bennett, J. E., Dismukes, W. E., Duma, R. J., Medoff, G., Sande, M. A., Gallis, H., Leonard, J., Fields, B. T., Bradshaw, M., Haywood, H., et al. (1979) · New England Journal of Medicine · doi:10.1056/nejm197907193010303 · Cited by 863
Vermes, A. (2000) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/46.2.171 · Cited by 803
Aneuploidy and Isochromosome Formation in Drug-Resistant Candida albicans
Selmecki, A., Forche, A., & Berman, J. (2006) · Science · doi:10.1126/science.1128242 · Cited by 733
Noble, S. M., French, S., Kohn, L. A., Chen, V., & Johnson, A. D. (2010) · Nature Genetics · doi:10.1038/ng.605 · Cited by 678
Resistance to Antifungal Agents: Mechanisms and Clinical Impact
Kanafani, Z. A., & Perfect, J. R. (2008) · Clinical Infectious Diseases · doi:10.1086/524071 · Cited by 619
Efflux-Mediated Antifungal Drug Resistance
Cannon, R. D., Lamping, E., Holmes, A. R., Niimi, K., Baret, P. V., Keniya, M. V., Tanabe, K., Niimi, M., Goffeau, A., & Monk, B. C. (2009) · Clinical Microbiology Reviews · doi:10.1128/cmr.00051-08 · Cited by 608
Azole resistance in Aspergillus fumigatus: a side-effect of environmental fungicide use?
Verweij, P. E., Snelders, E., Kema, G. H., Mellado, E., & Melchers, W. J. (2009) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(09)70265-8 · Cited by 604
Noble, S. M., & Johnson, A. D. (2005) · Eukaryotic Cell · doi:10.1128/ec.4.2.298-309.2005 · Cited by 592
Cited by
Campoy, S., & Adrio, J. L. (2017) · Biochemical Pharmacology · doi:10.1016/j.bcp.2016.11.019 · Cited by 511
Candidiasis and Mechanisms of Antifungal Resistance
Bhattacharya, S., Sae-Tia, S., & Fries, B. C. (2020) · Antibiotics · doi:10.3390/antibiotics9060312 · Cited by 474
Spampinato, C., & Leonardi, D. (2013) · BioMed Research International · doi:10.1155/2013/204237 · Cited by 411
Biofilm of Candida albicans : formation, regulation and resistance
Pereira, R., Santos Fontenelle, R. O., Brito, E. H. S., & Morais, S. M. (2021) · Journal of Applied Microbiology · doi:10.1111/jam.14949 · Cited by 368
Paulussen, C., Hallsworth, J. E., Álvarez‐Pérez, S., Nierman, W. C., Hamill, P. G., Blain, D., Rediers, H., & Lievens, B. (2017) · Microbial Biotechnology · doi:10.1111/1751-7915.12367 · Cited by 334
Clinical Appearance of Oral Candida Infection and Therapeutic Strategies
Patil, S., Rao, R. S., Majumdar, B., & Anil, S. (2015) · Frontiers in Microbiology · doi:10.3389/fmicb.2015.01391 · Cited by 324
Review on Antifungal Resistance Mechanisms in the Emerging Pathogen Candida auris
Chaabane, F., Graf, A., Jequier, L., & Coste, A. T. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.02788 · Cited by 223
Self-citationErg11 mutations associated with azole resistance in clinical isolates of Candida albicans
Xiang, M.-J., Liu, J.-Y., Ni, P.-H., Wang, S., Shi, C., Wei, B., Ni, Y.-X., & Ge, H.-L. (2013) · FEMS Yeast Research · doi:10.1111/1567-1364.12042 · Cited by 197
Ultrastructural analysis of Candida albicans when exposed to silver nanoparticles
Vazquez-Muñoz, R., Avalos-Borja, M., & Castro-Longoria, E. (2014) · PLoS ONE · doi:10.1371/journal.pone.0108876 · Cited by 168
“Furthermore, despite improvement of antifungal therapies over the last 30 years, antifungal resistance is still of major concern in clinical practice [10], and in general, the development of new antibiotics is a long and expensive process [11] which can now be resolved with the development of nanomaterials exhibiting…”
BackgroundExpandable and reversible copy number amplification drives rapid adaptation to antifungal drugs
Todd, R. T., & Selmecki, A. (2020) · eLife · doi:10.7554/elife.58349 · Cited by 138
“The evolution of antifungal drug resistance is an urgent threat to human health worldwide, particularly for hospitalized and immune-compromised individuals (Perea and Patterson, 2002; Pfaller, 2012; Vandeputte et al., 2012).”
BackgroundAntimicrobial Properties of Lauric Acid and Monolaurin in Virgin Coconut Oil: A Review
Nitbani, F. O., Tjitda, P. J. P., Nitti, F., Jumina, J., & Detha, A. I. R. (2022) · ChemBioEng Reviews · doi:10.1002/cben.202100050 · Cited by 137
Bondaryk, M., Kurzątkowski, W., & Staniszewska, M. (2013) · Advances in Dermatology and Allergology · doi:10.5114/pdia.2013.38358 · Cited by 126
Siles, S. A., Srinivasan, A., Pierce, C. G., Lopez-Ribot, J. L., & Ramasubramanian, A. K. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00680-13 · Cited by 120
Thangamani, S., Maland, M., Mohammad, H., Pascuzzi, P. E., Avramova, L., Koehler, C. M., Hazbun, T. R., & Seleem, M. N. (2017) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2017.00004 · Cited by 90
“Unfortunately, current antifungal therapies have limited effectiveness in treating invasive fungal infections and suffer from restrictions in route of administration, spectrum of activity, and bioavailability in target tissues such as the brain (Brown et al., 2012; Vandeputte et al., 2012).”
BackgroundWarrilow, A. G., Nishimoto, A. T., Parker, J. E., Price, C. L., Flowers, S. A., Kelly, D. E., Rogers, P. D., & Kelly, S. L. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02586-18 · Cited by 60
Holbrook, S. Y. L., Garzan, A., Dennis, E. K., Shrestha, S. K., & Garneau-Tsodikova, S. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.07.030 · Cited by 51
Repurposing FDA approved drugs against the human fungal pathogen, Candida albicans
Kim, K., Zilbermintz, L., & Martchenko, M. (2015) · Annals of Clinical Microbiology and Antimicrobials · doi:10.1186/s12941-015-0090-4 · Cited by 48
“These include: fluoropyrimidine analogs, polyenes, azoles, and echinocandins [9, 10].”
BackgroundEldesouky, H. E., Salama, E. A., Hazbun, T. R., Mayhoub, A. S., & Seleem, M. N. (2020) · Scientific Reports · doi:10.1038/s41598-020-62976-y · Cited by 33
Luna-Tapia, A., Kerns, M. E., Eberle, K. E., Jursic, B. S., & Palmer, G. E. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.04239-14 · Cited by 28
Endosomal Trafficking Defects Can Induce Calcium-Dependent Azole Tolerance in Candida albicans
Luna-Tapia, A., Tournu, H., Peters, T. L., & Palmer, G. E. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01034-16 · Cited by 12
Metadata
- Authors
- Vandeputte, P., Ferrari, S., & Coste, A. T.
- Venue
- International Journal of Microbiology
- Publisher
- Wiley
- Published
- 2012
- Volume
- 2012
- Pages
- 1-26
- ISSN
- 1687-918X (ISSN-L)
- 1687-9198
- OpenAlex
- W2070654910
- Cited by
- 505
- References
- 271
- FWCI
- 11.01
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.